Kazia Therapeutics EV/EBITDA
What is the EV/EBITDA of Kazia Therapeutics?
The EV/EBITDA of Kazia Therapeutics Limited is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on ASX compared to Kazia Therapeutics
What does Kazia Therapeutics do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Companies with ev/ebitda similar to Kazia Therapeutics
- NeonMind Biosciences has EV/EBITDA of N/A
- Lumos Diagnostics has EV/EBITDA of N/A
- Bluewater Acquisition Corp has EV/EBITDA of N/A
- Guyana Goldstrike Inc has EV/EBITDA of N/A
- BrewBilt Manufacturing has EV/EBITDA of N/A
- Sable Resources has EV/EBITDA of N/A
- Kazia Therapeutics has EV/EBITDA of N/A
- engage:BDR has EV/EBITDA of N/A
- Viaan Industries has EV/EBITDA of N/A
- Antera Ventures Ii Corp has EV/EBITDA of N/A
- MacDonald Mines Exploration has EV/EBITDA of N/A
- Sihayo Gold has EV/EBITDA of N/A
- Fabled Copper has EV/EBITDA of N/A